EDMUS

Collongues N, Cabre P, Marignier R, Zéphir H, Papeix C, Audoin B, Lebrun-Frenay C, Pelletier J, Fontaine B, Vermeersch P, Confavreux C, de Seze J. Arch Neurol 2011; 68: 918-924. A Benign Form of Neuromyelitis Optica. Does it exist?

Collongues N, Marignier R, Zéphir H, et al. Neurology 2010; 74: 736-742. Neuromyelitis optica in France: a multicenter study of 125 patients.

Wiendl H, Tokya KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. J Neurol 2008; 255: 1149-1463. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. Multiple Sclerosis Therapy Consensus Group (MSTCG).

Mikaeloff Y, Cardade G, Tardieu M, Suissa S; KIDSEP study group of the French Neuropediatric Society. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol 2008; 12: 205-209.

Rudick AR, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F and Panzara MA for the AFFIRM and SENTINEL investigators. Health-related qualify of life in multiple sclerosis: effects of Natalizumab. Ann Neurol 2007; 62: 335-346.

Calabresi PA, Giovannoni G, Confavreux C, Galetta L, Havrdova E, Hutchinson M, Kappos L, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, for the AFFIRM and SENTINEL investigators. The incidence and significance of anti-natalizumab antibodies. Neurology 2007; 69: 1391-1403.

Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, and the PROMiSe Trial Study Group. Glatiramer Acetate in primary progressive multple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA and Sandrock AW for the SENTINEL investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006; 354: 911-923.

Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, and Filippi M, for the European Study Group on Interferon Beta-1b in Secondary Progressive MS. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β–1b. Neurology 2003; 60: 1462-1466.

Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J and Miller D for the European Study Group in Interferon β–1b in Secondary Progressive MS. Neutralizing antibodies during treatment of secondary progressive MS with interferon β–1b. Neurology 2003; 60: 37-43.

Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R,Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. A randomised, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-1517.

Trojano M, Liguori M, Bosco Zimatore G, Bugarini R, Avolio C, Paolicelli D, Giuliani F, De Robertis F, Marrosu MG, Livrea P. Age-related disability in multiple sclerosis. Ann Neurol 2002; 51: 475-480.

Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, and Weinshenker B for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial. Neurology 2002; 59: 1496-1506.

Kappos L, Polman C, Pozzilli C, Thomspon A, Beckmann K, Dahlke F, and the European Study Group in Interferon β-1b in Secondary Progressive MS. Final analysis of the European multicenter trial on IFNβ–1b in secondary-progressive MS. Neurology 2001; 57: 1969-1975.

Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T and Miller DH for the European Study Group on Interferon Beta-1b in Secondary Progressive MS. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001; 57: 2191-2197.

Tourbah A, Berry I pour le groupe d'étude de l'IRM dans la SEP, coordonné par l'ARSEP. Recommandations pour la pratique de l'IRM dans la SEP. Revue Neurologique (Paris) 2001; 157: 122-125.

Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L & the altered peptide ligand in relapsing MS study group. Induction of a non-encephalitogenic type 2T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Medicine 2000; 6: 1176-1182.

Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH and the European Study Group on Interferon ß-1b in secondary progressive multiple sclerosis. The effect of interferon ß-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000; 123: 2256-2263.

Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K, European Study Group on Interferon ß-1b in secondary progressive MS. Effect on interferon ß-1b on MRI outcomes in secondary progressive multiple sclerosis: results of a European multicentre, randomised, double-blind, placebo-controlled trial. Annals of Neurology 1999; 46: 850-859.

Fischer JS, Rudick RA, Cutter GR and Reingold SC for the National MS Society Clinical Outcomes Assessment Task Force. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome measure. Multiple Sclerosis 1999; 5: 244-250.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.

Pachai C, Zhu YM, Grimaud J, Hermier M, Dromigny-Badin A, Boudraa A, Gimenez G, Confavreux C, Froment JC. A pyramidal approach for automatic segmentation of multiple sclerosis lesions in brain MRI. Computerized Medical Imaging and Graphics 1998; 22: 399-408.

Murphy N, Confavreux C, Haas J, König N, Sailer M, Swash M, Roullet E, Young C, the Cost of Multiple Sclerosis Group, and Merot JL. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998; 13: 607-622.

European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.

Murphy N, Confavreux C, Haas J, König N, Roullet E, Sailer M, Swash M, Young C, the Cost of Multiple Sclerosis Group, and Merot JL. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Journal of Neurology, Neurosurgery and Psychiatry 1998; 65: 460-466.

European Study Group on Interferon ß-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive mutliple sclerosis. Lancet 1998; 352: 1491-1497.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force. Annals of Neurology 1997; 42: 379-382.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Raos S, Reingold S, Syndulko K, Thompson A, Wallengerg J, Weinshenkier B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Annals of Neurology 1996; 40: 469-479.

Brochet B, Guinot P, Orgogozo JM, Confavreux C, Rumbach L, Lavergne V, and the gingkolide Study Group in multiple sclerosis. Double-blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1995; 58: 360-362.